Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.
Yuting YuanYue ZhangMin LeiXiying GuoXiaosong YangChanghan OuyangChao LiuQing-Jie ChenPublished in: International journal of endocrinology (2024)
DPP4 inhibitors significantly improved type 2 diabetic mellitus individuals' cognitive impairment and reduced fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. Subgroup analysis showed that people aged 60 to 70 years had better treatment effects at 0-180 days. This trial is registered with CRD42023399473.
Keyphrases
- blood glucose
- cognitive impairment
- systematic review
- blood pressure
- glycemic control
- phase iii
- type diabetes
- meta analyses
- clinical trial
- study protocol
- randomized controlled trial
- open label
- wound healing
- combination therapy
- cerebral ischemia
- insulin resistance
- metabolic syndrome
- weight loss
- blood brain barrier
- replacement therapy
- smoking cessation
- data analysis
- double blind